带状疱疹疫苗市场机会、成长驱动因素、产业趋势分析与预测 2025 - 2034 年

2024 年全球带状疱疹疫苗市场估值为49 亿美元，预计2025 年至2034 年将以10.1% 的复合年增长率强劲增长。对带状疱疹认识的提高预防和併发症。

对大众（尤其是老年人）进行带状疱疹风险教育的努力极大地促进了疫苗的采用。卫生组织强调疫苗接种在减轻严重併发症（包括慢性疼痛）方面的好处。这些活动鼓励采取积极主动的健康措施，特别是针对老年人及其照护人员，进一步推动市场扩张。

公共卫生运动和教育计划显着提高了人们尤其是老年人对带状疱疹风险的认识。卫生组织正在积极强调疫苗接种在预防疾病和最大程度地减少慢性疼痛的机会方面的重要性。因此，越来越多的老年人及其照护者选择接种疫苗作为预防性保健措施，推动带状疱疹疫苗市场的扩张。

该市场按产品分为Shingrix、Zostavax和SKYZoster，其中Shingrix以2024年42亿美元的收入引领市场。该疫苗的持久免疫力减少了频繁加强接种的需要，增强了其作为一种经济高效且可靠的选择的吸引力。

依疫苗类型，市场分为重组疫苗和减毒活疫苗。重组疫苗在 2024 年占据主导地位，预计到 2034 年将达到 113 亿美元。它们的免疫持续时间较长，无需重复给药，这使它们成为比减毒活疫苗更好的选择。

北美带状疱疹疫苗市场到 2024 年将创造 27 亿美元的收入。针对 50 岁及以上成年人接种带状疱疹疫苗的建议已被广泛采用，并得到 Medicare 和私人保险公司提供的保险范围的支持。人口老化和积极的健康措施进一步巩固了该地区的市场地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 老年人口不断增加
    • 疫苗开发的进展
    • 优惠报销政策
    • 人们对带状疱疹及其併发症的认识不断提高
  • 产业陷阱与挑战
    • 严格的监管要求
• 成长潜力分析
• 监管环境
• 2023 年定价分析
• 管道分析
• 技术景观
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2034 年

• 主要趋势
• 欣格里克斯
• 佐斯塔瓦克斯
• 天空佐斯特

第 6 章：市场估计与预测：按疫苗类型，2021 - 2034 年

• 主要趋势
• 重组疫苗
• 减毒活疫苗

第 7 章：市场估计与预测：按地区划分，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 8 章：公司简介

• GSK plc
• Merck & Co.
• SK bioscience

The Global Shingles Vaccine Market was valued at USD 4.9 billion in 2024 and is projected to grow at a robust CAGR of 10.1% from 2025 to 2034. Key factors driving this growth include the increasing aging population, improved reimbursement frameworks, and heightened awareness about shingles prevention and complications.

Efforts to educate the public about shingles risks, particularly among older adults, have significantly boosted vaccine adoption. Health organizations are emphasizing the benefits of vaccination in mitigating severe complications, including chronic pain. These campaigns encourage proactive health measures, particularly among the elderly and their caregivers, further fueling the market expansion.

Public health campaigns and educational programs have significantly increased awareness of the risks posed by shingles, especially among older adults. Health organizations are proactively highlighting the importance of vaccination in preventing the disease and minimizing the chances of chronic pain. Consequently, a growing number of elderly individuals and their caregivers are choosing vaccination as a preventive healthcare step, driving the expansion of the shingles vaccine market.

The market is segmented by product into Shingrix, Zostavax, and SKYZoster, with Shingrix leading the market by generating USD 4.2 billion in revenue in 2024. Its recombinant formulation provides durable and effective protection, particularly for high-risk groups such as older adults. The vaccine's long-lasting immunity reduces the need for frequent boosters, enhancing its appeal as a cost-effective and reliable option.

By vaccine type, the market is categorized into recombinant and live attenuated vaccines. The recombinant vaccine segment dominated in 2024 and is forecasted to reach USD 11.3 billion by 2034. These vaccines demonstrate superior efficacy, offering 90% protection even among vulnerable populations. Their extended immunity duration eliminates the need for repeated doses, making them the preferred choice over live attenuated options.

North America shingles vaccine market generated USD 2.7 billion in 2024. This dominance is driven by high awareness levels, supportive healthcare policies, and strong public health advocacy. Recommendations for shingles vaccination for adults aged 50 and older have been widely adopted, supported by accessible insurance coverage through Medicare and private insurers. The aging demographic and proactive health initiatives further strengthen the region's market position.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising geriatric population
    • 3.2.1.2 Advancements in vaccine development
    • 3.2.1.3 Favourable reimbursement policies
    • 3.2.1.4 Growing awareness about shingles and its complications
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pricing analysis, 2023
• 3.6 Pipeline analysis
• 3.7 Technology landscape
• 3.8 Future market trends
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Shingrix
• 5.3 Zostavax
• 5.4 SKYZoster

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Recombinant vaccine
• 6.3 Live attenuated vaccine

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 GSK plc
• 8.2 Merck & Co.
• 8.3 SK bioscience